Pecknold J C, Matas M, Howarth B G, Ross C, Swinson R, Vezeau C, Ungar W
Department of Psychiatry, McGill University, Montreal, Quebec.
Can J Psychiatry. 1989 Nov;34(8):766-71. doi: 10.1177/070674378903400804.
Buspirone has previously been demonstrated to be efficacious in the treatment of anxiety. This four-week double-blind parallel study compared buspirone to diazepam and placebo in the treatment of 119 outpatients diagnosed as having generalized anxiety disorder. After a seven-day placebo washout period, eligible patients were randomized to one of three treatment groups. Buspirone (5 mg) and diazepam (5 mg) were administered BID and individually titrated to an optimal therapeutic dose by the end of week two. Buspirone and diazepam were equally effective in reducing Hamilton Anxiety (HAM-A) total and psychic factor scores from baseline values. Buspirone alone was significantly better than placebo in reducing the HAM-A somatic factor score. Sixty-seven percent of both active treatment groups who were classified as "ill" on the baseline global psychopathology rating scale achieved a "not ill" status by study end. There were no significant differences between treatment groups at endpoint on the 56-item Symptom Checklist self-rating scale. Buspirone was demonstrated to be as effective as diazepam in relieving anxiety in this outpatient sample.
此前已证明丁螺环酮在治疗焦虑症方面有效。这项为期四周的双盲平行研究，将丁螺环酮与地西泮和安慰剂相比较，用于治疗119名被诊断为广泛性焦虑症的门诊患者。在为期七天的安慰剂洗脱期后，符合条件的患者被随机分配到三个治疗组之一。丁螺环酮（5毫克）和地西泮（5毫克）每日两次给药，并在第二周结束时分别滴定至最佳治疗剂量。丁螺环酮和地西泮在降低汉密尔顿焦虑量表（HAM - A）总分和心理因子得分方面，与基线值相比效果相当。单独使用丁螺环酮在降低HAM - A躯体因子得分方面显著优于安慰剂。在基线总体精神病理学评定量表上被归类为“患病”的两个活性治疗组中，67%的患者在研究结束时达到了“未患病”状态。在56项症状自评量表上，治疗组在终点时没有显著差异。在这个门诊样本中，丁螺环酮被证明在缓解焦虑方面与地西泮效果相当。
